Immunomedics Provides Update On Antibody-drug Conjugate Trials - Quick Facts

(RTTNews) - Immunomedics Inc. (IMMU) announced the three Phase I trials evaluating its antibody-drug conjugates in patients with diverse solid tumors have now advanced to Phase II clinical trials.

IMMU-130, labetuzumab-SN-38, was being studied in two different Phase-I dose-finding trials in patients with advanced colorectal cancer, after failing several prior therapies. IMMU-132, the anti-Trop-2-SN-38 ADC, was being evaluated in a single dose-escalation trial in late-stage metastatic cancer patients with multiple solid tumor types after failing several prior therapies. The purpose of the trials was to determine a tolerable dose that could be administered in repeated cycles, and any early evidence of efficacy.

"The optimal dosing schedules for IMMU-130 and IMMU-132 have now been determined, and we have advanced into Phase II clinical trials. We will continue to expand these programs," commented the company's President and CEO, Cynthia Sullivan.